Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Squamous Cell Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Esophageal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Capecitabine

Nedaplatin

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Patients in cohort A receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 60Gy combined with Capecitabine.

Patients in cohort B receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 50Gy combined with Capecitabine.

Toripalimab 240 mg, d1, Q3w for two cycles

Toripalimab

Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles

Paclitaxel-albumin

Nedaplatin 75mg/m2, d1, Q3w for two cycles

radiation therapy at a total dose 60 Gy

Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy

radiation therapy at a total dose 50 Gy

Hui Liu, Professor

This Phase II non-randomized study is to determine the efficacy and toxicity of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.

This Phase II non-randomized study is to determine the efficacy and toxicity of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.

All patients were planned to receive 2 cycle of toripalimab plus paclitaxel/nedaplatin as neoadjuvant therapy. Then they all receive radical dose of chest radiation and concurrent chemotherapy of capecitabine (PO 1000 mg/m2, bid, d1-d14, q3w).

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

the percentage of patients who had partial remission or complete remission after therapy

the percentage of patients who develop grade 3 or 4 toxicities

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	NCT04844385	Esophageal Squa...	Toripalimab Paclitaxel-albu... Nedaplatin radiation thera... Capecitabine radiation thera...	18 Years - 80 Years	Sun Yat-sen University
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	NCT04844385	Esophageal Squa...	Toripalimab Paclitaxel-albu... Nedaplatin radiation thera... Capecitabine radiation thera...	18 Years - 80 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for toripalimab, neoadjuvant, concurrent chemoradiotherapy, esophageal squamous cell carcinoma